Gene therapy restores vision in a canine model of childhood blindness
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The relationship between the neurosensory photoreceptors and the adjacent retinal pigment epithelium (RPE) controls not only normal retinal function, but also the pathogenesis of hereditary retinal degenerations. The molecular bases for both primary photoreceptor and RPE diseases that cause blindness have been identified. Gene therapy has been used successfully to slow degeneration in rodent models of primary photoreceptor diseases, but efficacy of gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported. Here we study one of the most clinically severe retinal degenerations, Leber congenital amaurosis (LCA). LCA causes near total blindness in infancy and can result from mutations in RPE65 (LCA, type II; MIM 180069 and 204100). A naturally occurring animal model, the RPE65-/- dog, suffers from early and severe visual impairment similar to that seen in human LCA. We used a recombinant adeno-associated virus (AAV) carrying wild-type RPE65 (AAV-RPE65) to test the efficacy of gene therapy in this model. Our results indicate that visual function was restored in this large animal model of childhood blindness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [64]
Citations
Cites
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Identification of the gene responsible for Best macular dystrophy
Petrukhin, K., Koisti, M. J., Bakall, B., Li, W., Xie, G., Marknell, T., Sandgren, O., Forsman, K., Holmgren, G., Andreasson, S., et al. (1998) · Nature Genetics · doi:10.1038/915 · Cited by 689
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N., & Hauswirth, W. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6916 · Cited by 407
Self-citationBiochemistry of visual pigment regeneration: the Friedenwald lecture.
Saari, J. C. (2000) · PubMed · Cited by 270
Simon, A., Hellman, U., Wernstedt, C., & Eriksson, U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1107 · Cited by 254
Van Hooser, J. P., Aleman, T. S., He, Y.-G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., & Palczewski, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150236297 · Cited by 252
Self-citationAguirre, G. K., Baldwin, V. J., Pearce‐Kelling, S., Narfström, K. L., Ray, K., & Acland, G. M. (1998) · PubMed · Cited by 244
Self-citationBennett, J., Maguire, A. M., Cideciyan, A. V., Schnell, M., Glover, E., Anand, V., Aleman, T. S., Chirmule, N., Gupta, A. R., Huang, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9920 · Cited by 242
Self-citation
Cited by
Items 801–900 of 1,000
In vivo study of response threshold in retinal degenerate model at different degenerate stages
Chan, L. H., Ray, A., Thomas, B. B., Humayun, M. S., & Weiland, J. D. (2008) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2008.4649523 · Cited by 9
“Potential treatments of RP include gene therapy [6], stem cells [7], and RPE and retinal transplantation [8].”
BackgroundLongitudinal evaluation of expression of virally delivered transgenes in gerbil cone photoreceptors
Mauck, M. C., Mancuso, K., Kuchenbecker, J. A., Connor, T. B., Hauswirth, W. W., Jay Neitz, A., & Neitz, M. (2008) · Visual Neuroscience · doi:10.1017/s0952523808080577 · Cited by 9
“Recombinant adeno-associated virus ~rAAV! holds promise as a means of delivering therapeutic genes to the retina ~Acland et al., 2001, 2005; Bainbridge et al., 2006; Pang et al., 2006! and as an experimental tool for probing the neural circuitry for vision ~Mancuso et al., 2007!.”
MethodSelf-citationPitkänen, L. (2007) · Cited by 9
Hollingsworth, T., Wang, X., White, W. A., Simpson, R. N., & Jablonski, M. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.839424 · Cited by 9
“While gene therapy for one form LCA has already been FDA-approved (LCA caused by RPE65 mutations), one must now consider the age of the subjects that need to be treated (Acland et al., 2001; Narfstrom et al., 2003).”
BackgroundConsensus guidelines for nomenclature of companion animal inherited retinal disorders
Mowat, F. M., Iwabe, S., Aguirre, G. D., & Petersen‐Jones, S. M. (2024) · Veterinary Ophthalmology · doi:10.1111/vop.13185 · Cited by 8
“…was identified to harbor a retinal disease-causing mutation in RPE65 , 7 and subsequently contributed extensively to the translation of RPE65 retinal gene augmentation therapy into humans, 8–10 This therapy is now commercialized after approval by regulatory agencies in the United States and Europe.”
Self-citationSalvaging Ruins: Reverting Blind Retinas into Functional Visual Sensors
Mutter, M., Swietek, N., & Münch, T. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0470-9_10 · Cited by 10
Oh, A., Loew, E. R., Foster, M. L., Davidson, M. G., English, R. V., Gervais, K. J., Herring, I. P., & Mowat, F. M. (2018) · Documenta Ophthalmologica · doi:10.1007/s10633-018-9653-y · Cited by 10
Brodsky, M. C. (2009) · Springer eBooks · doi:10.1007/978-0-387-69069-8_1 · Cited by 8
Narfström, K. L., Jeong, M., Hyman, J. A., Madsen, R., & Bergström, T. F. (2012) · Stem Cells International · doi:10.1155/2012/685901 · Cited by 9
“Mutations in the RPGRIP1 gene have been identified as causative to human RP, LCA, and cone-rod dystrophies [17–19].”
BackgroundInfluentialPlasticity in the Visual System
Pinaud, R., Tremere, L. A., & Weerd, P. D. (2006) · Springer eBooks · doi:10.1007/0-387-28190-8 · Cited by 61
SEVİK, M. O., & ŞAHİN, Ö. (2021) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0257 · Cited by 8
“…gene replacement therapy in a Swedish Briard-Beagle dog model for RPE65-related LCA suggests that such treatment may become possible in humans in the foreseeable future, especially now that sustained rescue of photoreceptor and RPE cells has been shown (Acland et al. 2001; Narfstrom et al. 2003).”
Lentiviral Gene Transfer-Mediated Cone Vision Restoration in RPE65 Knockout Mice
Bemelmans, A., Kostic, C., Cachafeiro, M. C. B., Crippa, S. V., Wanner, D., Tekaya, M., Wenzel, A., & Arsenijévic, Y. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74904-4_9 · Cited by 9
Saari, J. C. (2001) · Nature Genetics · doi:10.1038/ng0901-8 · Cited by 12
Assessment of rAAV-Mediated Gene Therapy in the Rpe65-/- Mouse
Rakoczy, P. E., Lai, C., Yu, M. J. T., Daniels, D. M., Brankov, M., Rae, B. C., Stoddart, C. W., Barnett, N. L., Martin-Iverson, M. T., Redmond, T. M., et al. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0067-4_55 · Cited by 8
Ham, D., Fujimoto, C., Gentleman, S., Chan, C., Yu, C., Yu, S., Egwuagu, C. E., Redmond, T. M., & Gery, I. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.04.013 · Cited by 8
Antisense Therapeutics for Hypertension: Targeting the Renin–Angiotensin System
Phillips, M. I., & Kimura, B. (2004) · Humana Press eBooks · doi:10.1385/1-59259-854-4:051 · Cited by 8
Viral Vectors for Gene Therapy
Linden, R. M., & Berns, K. I. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0274 · Cited by 9
CRISPR-Cas9 and Its Therapeutic Applications for Retinal Diseases
Lin, W. V., Stout, J. T., & Weng, C. Y. (2018) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000252 · Cited by 7
A Retinal Research Nonprofit Paves the Way for Commercializing Gene Therapies
Shaberman, B. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.29058.bsh · Cited by 7
Bhattacharjee, S., Davies, D. C., Holland, J., Holmes, J. M., Kilroy, D., McGonnell, I. M., & Reynolds, A. (2021) · Journal of Anatomy · doi:10.1111/joa.13570 · Cited by 11
“Using an AAV2- based vector to deliver genetic materials by subretinal injection has given promising results in restoring vision in the Briard LCA model (Acland et al., 2001), with a single injection demonstrated to reverse the pathology (Wang et al., 2020).”
MethodHitti‐Malin, R. J., Burmeister, L. M., Lingaas, F., Kaukonen, M. K., Pettinen, I., Lohi, H., Sargan, D. R., & Mellersh, C. S. (2021) · Genes · doi:10.3390/genes12111771 · Cited by 7
Klein, D., Mendes-Madeira, A., Schlegel, P., Rolling, F., Lorenz, B., Haverkamp, S., & Stieger, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086304 · Cited by 10
Fan, J., Crouch, R. K., & Kono, M. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6437 · Cited by 9
Spinocerebellar Ataxia Type 7: Clinical Features to Cellular Pathogenesis
Garden, G. A., Truant, R., Ellerby, L., & Spada, A. R. L. (2006) · Elsevier eBooks · doi:10.1016/b978-012369462-1/50028-4 · Cited by 8
Adeno‐associated viral vectors for gene therapy
Flotte, T. R., & Berns, K. I. (2005) · Laboratory techniques in biochemistry and molecular biology · doi:10.1016/s0075-7535(05)31001-1 · Cited by 7
Clinical and Molecular Genetic Aspects of Leber’s Congenital Amaurosis
Henderson, R., Lorenz, B., & Moore, A. T. (2006) · Springer eBooks · doi:10.1007/3-540-31220-x_10 · Cited by 7
Molecular Genetics of Retinal Disease
Brown, J., Webster, A. R., Sheffield, V. C., & Stone, E. M. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-02598-0.50022-7 · Cited by 7
Looking into anti-angiogenic gene therapies for disorders of the eye
Rasmussen, H. S., Rasmussen, C. S., Durham, R. G., King, C. R., & Wei, L. L. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02034-7 · Cited by 7
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A., & Fisson, S. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.191 · Cited by 6
Genetics of Leber congenital amaurosis: an update
Shukla, R., Kannabiran, C., & Jalali, S. (2012) · Expert Review of Ophthalmology · doi:10.1586/eop.12.14 · Cited by 7
Development and validation of the canine visual function instrument
Miller, W. W., & Parisi, D. (2018) · Veterinary Ophthalmology · doi:10.1111/vop.12551 · Cited by 6
Dai, X., Jin, X., Ye, Q., Huang, H., Duo, L., Lu, C., Bao, J., & Chen, H. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108776 · Cited by 7
Narfström, K. L., Tullis, G. E., & Seeliger, M. W. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-186-4_22 · Cited by 6
La transplantation de photorécepteurs immatures
Léveillard, T., Mohand‐Saïd, S., & Sahel, J. (2007) · médecine/sciences · doi:10.1051/medsci/2007233240 · Cited by 6
Palczewski, K. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.245 · Cited by 7
Genersatztherapie bei genetisch bedingter Zapfenblindheit
Mühlfriedel, R., Tanimoto, N., & Seeliger, M. W. (2014) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0034-1368180 · Cited by 8
The Perceptual Effects of Chronic Retinal Stimulation
Horsager, A., & Fine, I. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0754-7_14 · Cited by 9
“For example, gene replacement therapy efforts have made great progress in treating one form of Leber’s Congenital Amaurosis (an RPE65 mutation) in humans [1, 2, 4, 7, 8, 52]; however, this form of RP is relatively rare, and photoreceptor diseases are genetically heterogeneous, with single and multi-gene mutations occu…”
Genetics, phenotypes, mechanisms and treatments for Leber congenital amaurosis: a paradigm shift
Koenekoop, R. K., López, I., Allikmets, R. L., Cremers, F. P. M., & den Hollander, A. I. (2008) · Expert Review of Ophthalmology · doi:10.1586/17469899.3.4.397 · Cited by 7
Viral vectors for targeting the canine retina: a review
Petersen‐Jones, S. M. (2012) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2012.01054.x · Cited by 8
“Gene supplementation therapy in the RPE65-mutant dog achieves a dramatic restoration of dim light vision and retinal function as assessed by electroretinography [6,7,20,21].”
BackgroundFunctional Assessment of Vision Restoration
McGregor, J. E., Williams, D. R., & Merigan, W. H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_24 · Cited by 8
Drug and gene therapy of hereditary retinal disease in dog and cat models
Petersen‐Jones, S. M. (2013) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2014.01.002 · Cited by 7
Entrainment of circadian rhythm to a photoperiod reversal shows retinal dystrophy in RPE65−/− mice
Daniels, D. M., Stoddart, C. W., Martin-Iverson, M. T., LAI, C., Redmond, T. M., & Rakoczy, P. E. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00202-6 · Cited by 6
A 350 bp region of the proximal promoter of Rds drives cell-type specific gene expression
Cai, X., Conley, S. M., Cheng, T., Al‐Ubaidi, M. R., & Naash, M. I. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.04.017 · Cited by 9
“…a popular and promising therapeutic approach for the treatment of inherited retinal degenerations in various animal models and patients [rodents (Ali et al., 2000; Cai et al., 2009b; Weber et al., 2003), dogs (Acland et al., 2005, 2001; Le Meur et al., 2006), primates (Jacobson et al., 2006;…”
BackgroundThe Role of RPE65 in Inherited Retinal Diseases
Bok, D. (2005) · Retina · doi:10.1097/00006982-200512001-00028 · Cited by 7
Shen, W., Lai, Y. K. Y., Lai, C., & Rakoczy, P. E. (2003) · Vision Research · doi:10.1016/j.visres.2003.09.032 · Cited by 7
Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Hamel, C., Dufier, J., Rozet, J., & Kaplan, J. (2005) · Journal Français d Ophtalmologie · doi:10.1016/s0181-5512(05)81031-9 · Cited by 11
“[48] d’expérience réussie de thérapie génique chez le chien Briard.”
Pan, Y., Zhai, P. C., Dashti, A., Wu, S., Lin, X., & Wu, M. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00241-0 · Cited by 6
Eyes shut homolog (EYS): Connecting molecule to disease
Marques, J. P., Sousa, I. S., Patrício, D., Simões, B. F., Chukwunalu, O., Zeitz, C., Audo, I. S., Collin, R. W. J., Quinn, P. M. J., Ambrósio, A. F., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101391 · Cited by 6
Rowe, A. A., Chen, X., Nettesheim, E. R., Issioui, Y., Dong, T., Hu, Y., Messahel, S., Kayani, S. N., Gray, S. J., & Wert, K. J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104314 · Cited by 6
Canine models of inherited retinal diseases: from neglect to well-recognized translational value
Dufour, V., & Aguirre, G. D. (2024) · Mammalian Genome · doi:10.1007/s00335-024-10091-y · Cited by 5
“Soon after, we showed that the review was premature and incorrect (Acland et al. 2001).”
InfluentialSelf-citationAdeno-associated virus (AAV) based gene therapy for eye diseases
Wang, S., Liu, P., Song, L., Lü, L., Zhang, W., & Ya-zhen, W. (2011) · Cell and Tissue Banking · doi:10.1007/s10561-011-9243-7 · Cited by 5
“It was also showed that AAV2 based subretinal delivery of wild type RPE65 protein could restore the visual function and retina morphology as well as the ERG signals (Acland et al. 2005, 2001; Narfstrom et al. 2003a, b).”
BackgroundSmall Molecule-Based Inducible Gene Therapies for Retinal Degeneration
Datta, S., Peng, H., & Hulleman, J. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_11 · Cited by 5
RNA-based therapies in animal models of Leber congenital amaurosis causing blindness
Wang, X., Shan, X., Gregory-Evans, K., & Gregory, C. Y. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa009 · Cited by 6
Viral Vectors in Gene Therapy and Clinical Applications
Mahoney, A. L. G., Nassif, N. T., O’Brien, B. A., & Simpson, A. M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102559 · Cited by 8
Li, R. T. H., Román, A. J., Sumaroka, A., Stanton, C. M., Świder, M., Garafalo, A. V., Héon, E., Vincent, A., Wright, A. F., Megaw, R. D., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.15.33 · Cited by 6
Self-citationAmato, A., Tschetter, W. W., Everett, L. A., Bailey, S. T., Lauer, A. K., Yang, P. G., & Pennesi, M. E. (2024) · Documenta Ophthalmologica · doi:10.1007/s10633-024-09987-6 · Cited by 5
“[ 33] Even though animal models in preclinical studies were treated at an early developmental stage [7, 34–37], most clinical trials did not find an association between age at time of treatment and visual outcomes [38–42].”
Gene Therapy for Retinitis Pigmentosa
Tomita, H., Sugano, E., Isago, H., Murayama, N., & Tamai, M. (2013) · InTech eBooks · doi:10.5772/52987 · Cited by 5
“Indeed, successful results have been reported in RPE65 replacement therapy with the LCA2 animal model, Briard dogs [15].”
ResultAn Adeno-Associated Virus Vector Efficiently and Specifically Transduces Mouse Skeletal Muscle
Murakami, I., Takeuchi, T., Mori‐Uchino, M., Mori, S., Fujii, T., Aoki, D., Nakagawa, K., & Kanda, T. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9369-z · Cited by 5
NILSSON, S. E. G. (2006) · Acta Ophthalmologica Scandinavica · doi:10.1111/j.1600-0420.2006.00751.x · Cited by 9
Molecular characterization of novel Adeno-associated virus variants infecting human tissues
Purohit, N., Jain, A., Mathews, V., & Jayandharan, G. R. (2019) · Virus Research · doi:10.1016/j.virusres.2019.197716 · Cited by 5
Precision Therapy for Inherited Retinal Disease
Koulisis, N., & Nagiel, A. (2020) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2020.02.007 · Cited by 5
Pasmanter, N., Occelli, L. M., & Petersen‐Jones, S. M. (2021) · Documenta Ophthalmologica · doi:10.1007/s10633-021-09832-0 · Cited by 5
Utility of the DHFR-based destabilizing domain across mouse models of retinal degeneration and aging
Peng, H., Ramadurgum, P., Woodard, D. R., Daniel, S., Nakahara, E., Renwick, M., Aredo, B., Datta, S., Chen, B., Ufret-Vincenty, R. L., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104206 · Cited by 5
“…Stein-Streilein, 2010), and ii) the FDA approval of a gene replacement therapy for the treatment of Leber’s congenital amaurosis 2 by using recombinant adeno-associated virus (rAAV) to drive expression of the wild-type (WT) RPE65 gene in retinal pigment epithelium (RPE) cells (Acland et al., 2001).”
BackgroundRetinoid therapy restores eye-specific cortical responses in adult mice with retinal degeneration
Huh, C. Y. L., Leinonen, H., Nakayama, T., Tomasello, J., Zhang, J., Zeitoun, J. H., Peach, J. P., Halabi, M., Kiser, J. Z., Palczewski, K., et al. (2022) · Current Biology · doi:10.1016/j.cub.2022.09.005 · Cited by 5
How to keep photoreceptors alive
Bird, A. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611014104 · Cited by 5
EL‐Mahdy, A. F. M., Shibata, T., Kabashima, T., Zhu, Q., & Kai, M. (2015) · RSC Advances · doi:10.1039/c5ra01032b · Cited by 5
Retinitis pigmentosa: genetics and gene-based approaches to therapy
Kannabiran, C. (2008) · Expert Review of Ophthalmology · doi:10.1586/17469899.3.4.417 · Cited by 6
Inherited diseases of photoreceptors and prospects for gene therapy.
Montana, C., & Corbo, J. (2008) · Pharmacogenomics (London) · doi:10.2217/14622416.9.3.335 · Cited by 7
Gene therapy clinical trials for inherited eye disease
Bainbridge, J. W. (2007) · Expert Review of Ophthalmology · doi:10.1586/17469899.2.4.517 · Cited by 8
[Viral vectors in gene therapy. Advantages of the adenoassociated vectors].
Rodríguez, A. S. S., Montes, A. M. S., & Armendáriz‐Borunda, J. (2005) · PubMed · Cited by 6
Ferreyra, H. A., & Heckenlively, J. R. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780195326147.003.0023 · Cited by 6
Gammon, K. (2012) · Nature Medicine · doi:10.1038/nm0612-847 · Cited by 5
Digging up the canine genome – a tale to wag about
Greer, K. A., Cargill, E. J., Cox, M. L., Clark, L. A., Tsai, K. L., Credille, K. M., Dunstan, R. W., Venta, P. J., & Murphy, K. E. (2003) · Cytogenetic and Genome Research · doi:10.1159/000075756 · Cited by 5
“Secondly, a form of early childhood blindness, Leber congenital amaurosis, has been corrected by gene therapy in a spontaneous canine model of the disease (Acland et al., 2001).”
BackgroundDowns, L. M., & Mellersh, C. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093990 · Cited by 4
The landscape of basic gene therapy approaches in inherited retinal dystrophies
Xia, J., Gu, L., & Pan, Q. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1193595 · Cited by 4
Tan, E. Y. S., Sing, S. L., & Yeong, W. Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102561-1.00027-0 · Cited by 5
Gene Editing and Gene Therapy in Oncology
Wierson, W. A., Abel, A. M., Siegler, E. L., Ekker, S. C., Johannes, C. M., Kenderian, S. S., & Mochel, J. P. (2023) · CABI eBooks · doi:10.1079/9781789245820.0009 · Cited by 3
How Advanced are Nanocarriers for Effective Subretinal Injection?
Guan, J.-X., Wang, Y.-L., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479327 · Cited by 5
Virale und nichtvirale Gentherapieansätze zur Behandlung von Netzhauterkrankungen
Neidhardt, J., Wycisk, K. A., & Kloeckener‐Gruissem, B. (2005) · Der Ophthalmologe · doi:10.1007/s00347-005-1245-z · Cited by 4
Therapy options for retinitis pigmentosa
Nakazawa, M. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.858596 · Cited by 8
“There has been remarkable progress in clinical applications of gene therapy for humans since it was successfully performed in a canine model of RPE65 deficiency [42].”
BackgroundBennett, J. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2529 · Cited by 4
“Later, psychophysical testing by Drs. S. Jacobson and A. Cideciyan (using electroretinograms) showed a restoration of retinal photoreceptor responses (Acland et al. , 2001).”
Self-citationChang, B. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3661-8_21 · Cited by 4
Retinitis Pigmentosa and Related Disorders
Sieving, P. A., & Caruso, R. C. (2009) · Elsevier eBooks · doi:10.1016/b978-0-323-04332-8.00083-4 · Cited by 5
Genes and Gene Therapy in Inherited Retinal Disease
Shughoury, A., Ciulla, T. A., Bakall, B., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000377 · Cited by 4
Clinical manifestation and current therapeutics in X-juvenile retinoschisis
Yang, Y.-P., Jheng, Y.-C., Chien, Y., Tsai, P.-H., Hwang, D.-K., Weng, C.-C., Huang, Y.-M., Hsu, C.-C., Chou, Y.-B., Chen, S.-J., et al. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000684 · Cited by 4
Genetically modified animal models of hereditary diseases for testing of gene-directed therapy
Polikarpova, A. V., Egorova, T. V., & Bardina, M. V. (2022) · Research Results in Pharmacology · doi:10.3897/rrpharmacology.8.82618 · Cited by 9
“Following subretinal injections, cone and rod ERGs improved and visual function was partially restored in both model RPE65-/- animals (Acland et al. 2001; Lai et al. 2004).”
BackgroundKoenekoop, R. K. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-186-4_3 · Cited by 4
Retinitis Pigmentosa and Associated Disorders
Drack, A. V., & KIMURA, A. E. (2007) · Springer eBooks · doi:10.1007/0-387-27933-4_5 · Cited by 4
Liu, X., Brandt, C. R., Rasmussen, C. A., & Kaufman, P. L. (2007) · Expert Review of Ophthalmology · doi:10.1586/17469899.2.2.227 · Cited by 4
Corneal Gene Therapy in Veterinary Medicine: A Review
Bosiack, A. P. (2013) · Journal of Veterinary Science & Technology · doi:10.4172/2157-7579.s8-001 · Cited by 4
“Pioneer efforts in gene therapy for congenital LCA has demonstrated significant improvement of visual impairment in affected Briard dogs and is being used to help restore vision in children [2].”
BackgroundThe Development of Visual Prosthetic Devices to Restore Vision to the Blind
Memon, M. A., & Rizzo, J. F. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374248-3.00060-4 · Cited by 4
Brodsky, M. C. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3384-6_1 · Cited by 4
Adeno‐associated Viral Vectors in Gene Therapy
Ling, C., Zhong, L., & Srivastava, A. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0005738.pub3 · Cited by 6
Recent Advances in Small Animal Genetics
Bannasch, D. L., & Hughes, A. M. (2006) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2005.12.004 · Cited by 4
Owens, G., Mistry, S., Edelman, G. M., & Crossin, K. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301780 · Cited by 4
Canine Best disease as a translational model
Aguirre, G. D., & Beltran, W. A. (2025) · Eye · doi:10.1038/s41433-024-03578-0 · Cited by 3
“Because of the success of AAV-mediated gene therapy for another primary RPE disease, RPE65 -LCA [20], we examined if AAV-mediated BEST1 gene augmentation would reverse the ongoing retinal abnormalities, and if expression/overexpression of the therapeutic transgene in the RPE was safe.”
Self-citationHuang, X., Wang, X., Feng, L., Zhou, R., Chen, W., Jiang, X., Lv, F., Xu, W., Xu, X., Xie, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123742 · Cited by 3
Biological Considerations for an Intraocular Retinal Prosthesis
Ameri, H., Weiland, J. D., & Humayun, M. S. (2007) · Springer eBooks · doi:10.1007/978-0-387-49331-2_1 · Cited by 6
“These experimental treatments include the following: gene therapy [27], stem cells [28], and RPE and retinal transplantation [29].”
BackgroundInvestigation of SLA4A3 as a candidate gene for human retinal disease
Downs, L. M., Webster, A. R., Moore, A. T., Michaelides, M., Ali, R. R., Hardcastle, A. J., & Mellersh, C. S. (2016) · Journal of Negative Results in BioMedicine · doi:10.1186/s12952-016-0054-z · Cited by 3
“For example, mutations in RPE65 have been implicated in AR retinal degeneration (LCA) in dogs [10, 11] and humans [12, 13], and gene therapy clinical trials have yielded promising results in both species [14–20].”
ResultGene Therapy for Retinal Diseases
Gopinath, C., Sarkar, S., & Ghosh, A. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_30 · Cited by 3
Metadata
- Authors
- Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., Jacobson, S. G., Hauswirth, W. W., & Bennett, J.
- Affiliations
- Cornell University (US)
- University of Pennsylvania (US)
- University of Florida (US)
- Corresponding author
- Bennett, Jean
- ORCID
- Venue
- Nature Genetics
- Published
- 2001-05
- Volume
- 28
- Issue
- 1
- Pages
- 92-95
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2141354154
- Cited by
- 1,202
- References
- 21
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 19 · 2023: 24 · 2022: 26 · 2021: 38 · 2020: 35 · 2019: 36 · 2018: 39 · 2017: 41 · 2016: 33 · 2015: 40 · 2014: 56 · 2013: 48 · 2012: 64
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ey011142-05)
- National Eye Institute (EY10820, EY 06855, R01EY010820, EY 11142, R01EY013132, R01EY011123, EY-11123, EY 13132)
- National Institute of Neurological Disorders and Stroke (NS36202)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, Leber congenital amaurosis, RPE65, retinal pigment epithelium, photoreceptors, recombinant adeno-associated virus, childhood blindness, vision restoration, inherited retinal degeneration, large animal model
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Animals, Blindness, Carrier Proteins, Disease Models, Animal, Dog Diseases, Dogs, Eye Proteins, Proteins, Genetic Therapy, Optic Atrophies, Hereditary, cis-trans-Isomerases, Animals, Genetically Modified
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.